RecruitingPhase 4NCT07145736

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases

Studying Ankylostomiasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kirby Institute
Principal Investigator
Susana V Nery, PhD
Kirby Institute, University of New South Wales, Australia
Intervention
Moxidectin(drug)
Enrollment
52000 enrolled
Eligibility
5 years · All sexes
Timeline
2025 – 2029

Study locations (1)

Collaborators

Emory University · La Trobe University · Murdoch Childrens Research Institute · Medicines Development for Global Health · University of Melbourne · Swiss Tropical & Public Health Institute · University of Ottawa · The Mentor Initiative · Erasmus Medical Center · Ministry of Health, Angola · The END Fund · Center for Research on Filariasis and Other Tropical Diseases, Cameroon · World Health Organization

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07145736 on ClinicalTrials.gov

Other trials for Ankylostomiasis

Additional recruiting or active studies for the same condition.

See all trials for Ankylostomiasis →

← Back to all trials